Skip to content

Stenting and Resection for Stage IV Colorectal Cancer Endoscopic Stenting and Colorectal Resection in Stage IV

Comparison Between Endoscopic Stenting and Colorectal Resection in Patients With Stage IV Colorectal Cancer

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03451643
Enrollment
50
Registered
2018-03-02
Start date
2013-02-28
Completion date
2020-02-29
Last updated
2018-03-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Neoplasm

Keywords

colorectal cancer, liver metastases, stage IV

Brief summary

Patients with Stage IV obstructing colorectal cancer and unresectable liver metastses, with general and local conditions not a risk for coliorectal resection, will be randomized to have either endoscopic stenting or colorectal resection

Detailed description

Patients with obstructing colorectal cancer, Stage IV with not resectable metastases will be considered . Patients with acceptable general and local conditions, to allow a safe surgical resection will be considered. Patients will be randomized to have endoscopic stenting or colorectal resection. All patients will receive postoperative chemio therapy

Interventions

PROCEDUREENDOSCOPIC PLACEMENT OF EXPANDABLE STENT

PLACEMENT OF AN ENDOSCOPIC SELF EXPANDABLE METAL STENT

Sponsors

University of Roma La Sapienza
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

RANDOMIZED CONTROLLED TRIAL

Eligibility

Sex/Gender
ALL
Age
50 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* Patients with Stage IV obstructing colorectal cancer and liver metastases * Liver metastases not resectable

Exclusion criteria

-Patients considered at high risk for colorectal resection

Design outcomes

Primary

MeasureTime frameDescription
MORTALITY60 DAYSTHE NUMBER OF POSTPROCEDURAL DEATHS
SURVIVAL5 YEARSSURVIVAL IN MONGTHS WILL BE DETERMINED FOR PATIENTS USING KAPLAN MEIER CURVES AND MEDIAN SURVIVAL
POSTOPERATIVE MORBIDITY60 DAYSMAJOR AND MINOR COMPLICATIONS AFTER THE PROCEDURE

Secondary

MeasureTime frameDescription
QUALITY OF LIFE5 YEARSQUALITY OF LIFE WILL BE ASSESSED USING A STANDARDIZED PROTOCOL

Countries

Italy

Contacts

Primary ContactANTONIO STERPETTI, MD
antonio.sterpetti@uniroma1.it39-6-49972188
Backup ContactENRICO FIORI, MD
enrico.fiori@uniroma1.it39-6-49972245

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026